Prescribing for patients with liver disease

Bailliere's Clinical Gastroenterology

Volumn 3, Issue 1, 1989, Pages 109-130

  Arns, P A ^a   Branch, R A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLISM; GLUCURONIDATION; HUMAN; LIVER CLEARANCE; LIVER DISEASE; LIVER FUNCTION; PHARMACOKINETICS; REVIEW; SULFATION;

HUMAN; LIVER DISEASES; PHARMACOKINETICS; PRESCRIPTIONS, DRUG; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024372132     PISSN: 09503528     EISSN: None     Source Type: Journal    
DOI: 10.1016/0950-3528(89)90049-3     Document Type: Article

References (187)

1. Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment
2. Kinetics of rifampin and isoniazid administered alone and in combination to normal subjects and patients with liver disease
3. Gross impairment of hepatic drug metabolism in a patient with chronic liver disease
4. The protein binding of some drugs in plasma from patients with alcoholic liver disease
5. Furosemide pharmacokinetics in patients with liver disease
6. Midazolam kinetics
7. The effect of liver disease in man on the disposition of phenobarbital
8. Paracetamol (Acetaminophen) clearance in patients with cirrhosis of the liver
9. Pharmacokinetics of diazepam in disordered liver function
10. The effect of cirrhosis on the disposition and elimination of clindamycin
11. Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver
12. Clinical pharmacology of Adriamycin (NSC-123127)
13. Influence of acute viral hepatitis on phenytoin kinetics and protein binding
14. Pharmacokinetics of cefoperazone in normal subjects and patients with hepatosplenic schistosomiasis
15. Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis
16. A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol
17. Intravenous administration of diazepam in patients with chronic liver disease
18. Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery
19. The effect of chronic alcoholic ingestion and alcoholic liver disease on binding of drugs to serum proteins
20. Effects of hepatic function on vancomycin clinical pharmacology
21. Altered elimination of antipyrine in patients with acute viral hepatitis
22. Naproxen disposition in hepatic and biliary disorders
23. Cimetidine disposition in patients with Laennec's cirrhosis during multiple dosing therapy
24. Binding and disposition of sulfisoxazole in alcoholic cirrhosis
25. Decreased extrarenal clearance of cefoperazone in hepatocellular diseases
26. Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency
27. Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis
28. Impaired elimination of caffeine in cirrhosis
29. Metabolism of procainamide and p-aminobenzoic acid in patients with chronic liver disease
30. The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis
31. Drug metabolism in liver disease: Activity of hepatic microsomal metabolizing enzymes
32. Disposition and metabolism of metronidazole in patients with liver failure
33. Alfentanil pharmacokinetics in patients with cirrhosis
34. Antipyrine, paracetamol, and lidocaine elimination in chronic liver disease
35. Paracetamol metabolism in chronic liver disease
36. Furosemide kinetics in patients with hepatic cirrhosis with ascites
37. Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt
38. Pharmacokinetics of furosemide in patients with hepatic cirrhosis
39. Pharmacokinetics of cimetidine in advanced cirrhosis
40. Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function
41. Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease
42. Clofibrate disposition in renal failure and acute and chronic liver disease
43. Altered disposition and availability of cimetidine in liver cirrhotic patients
44. The inhibition of drug metabolism by cimetidine in patients with liver cirrhosis
45. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis
46. Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects
47. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients
48. Guide to drug dosage in renal failure
49. Clinical pharmacokinetics of indomethacin
50. Disposition of aminopyrine, antipyrine, diazepam and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination
51. Use of clindamycin in patients with liver disease
52. Pharmacodynamics of carbenicillin in hepatic and renal failure
53. Decreased first-pass metabolism of labetalol in chronic liver disease
54. Plasma protein binding of diphenylhydantoin
55. Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics
56. Plasma half-life of phenylbutazone in patients with impaired liver function
57. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function
58. Antipyrine clearance in patients with Gilbert's syndrome
59. Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam
60. CSF concentrations and serum protein binding of carbamazepine and carbamazepine-10gll-epoxide in epileptic patients
61. Ibuprofen and sulindac kinetics in alcoholic liver disease
62. Effect of liver failure on the pharmacokinetics of cyclophosphamide
63. Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates and ethanol
64. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases
65. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide
66. Metabolism and pharmacokinetics of the antibiotic rifampin
67. Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol
68. Clinical experience with atenolol in patients with chronic liver disease
69. Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency
70. Nifedipine: Kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration
71. The effect of cirrhosis on the disposition and elimination of meperidine in man
72. The effects of age and liver disease on the disposition and elimination of diazepam in adult man
73. Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease
74. Disposition of valproic acid in patients with liver disease
75. Alterations in the disposition of differently cleared drugs in patients with cirrhosis
76. Effects of aging and liver disease on disposition of lorazepam
77. Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease
78. Pharmacokinetics of single-dose erythromycin in normal and alcohol liver disease subjects
79. Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis
80. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy
81. Effect of plasma protein binding of drugs on duration and intensity of pharmacological activity
82. Pharmacokinetics of ampicillin in cirrhosis
83. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics
84. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis
85. Effects of cirrhosis on kinetics of aztreonam
86. Effect of chronic liver disease on plasma levels and metabolism of digoxin and beta-methyl digoxin
87. Pharmacokinetics of theophylline in hepatic disease
88. Effects of interferon-inducing agents on hepatic cytochrome P-450 drug metabolizing systems
89. The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease
90. The metabolism of tritiated digoxin in cirrhotic patients
91. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction
92. Metabolism of amylobarbitone in patients with chronic liver disease
93. Clinical effects and metabolism of diazepam in patients with chronic liver disease
94. Effect of acute viral hepatitis in man on the disposition and elimination of meperidine
95. Antipyrine kinetics in liver disease and liver transplantation
96. Chlordiazepoxide, librium (L), therapy in hepatic insufficiency
97. Diphenhydramine disposition in chronic liver disease
98. Cholestasis and hepatic drug metabolism: Comparison of metabolic clearance rate of antipyrine in patients with intrahepatic or extrahepatic cholestasis
99. Antiviral activity and side effects of polyriboinosinic-cytidylic acid complexes as affected by molecular size
100. Pyran and polyribonucleotides: Differences in biological activities
101. Cefotaxime concentrations in ascites
102. Clinical pharmacokinetics of chlordiazepoxide in patients with alcoholic hepatitis
103. Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients
104. Pharmacokinetic study of chloramphenicol in patients with liver disease
105. Impairment of hepatic drug metabolism in patients with acute viral hepatitis
106. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis
107. The effect of cimetidine on hepatic drug elimination in cirrhosis
108. Cimetidine-induced mental confusion in patients with cirrhosis
109. Methadone disposition in patients with chronic liver disease
110. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients
111. Disease-related alterations in cardiac glycoside disposition
112. Repeated diazepam dosing in cirrhotic patients: Cumulation and sedation
113. Temazepam clearance unaltered in cirrhosis
114. Pharmacokinetics and protein binding of cefazolin and cephalothin in patients with cirrhosis
115. Elimination of pindolol in liver disease
116. Pharmacokinetic studies of cefuroxime in patients with liver cirrhosis
117. Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis
118. Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis
119. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure
120. Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction
121. Thiopental pharmacokinetics in patients with cirrhosis
122. Safety and pharmacokinetics of ceftazidime in patients with chronic hepatic dysfunction
123. Morphine metabolism in cirrhosis
124. Normal metabolism of morphine in cirrhosis
125. Renal function, protein binding and pharmacological response to diazoxide
126. Protein binding of salicylates and quinidine in plasma from patients with renal failure, chronic liver disease and chronic respiratory insufficiency
127. Clinical pharmacokinetics of digitoxin
128. Theophylline disposition in patients with hepatic cirrhosis
129. Liver size and indices of drug metabolism in alcoholics
130. Single-dose kinetics of primidone in acute viral hepatitis
131. Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver
132. Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects
133. Corticosteroids in liver disease: Studies on the biological conversion of prednisone to prednisolone and plasma protein binding
134. Blood levels of rifampicin in liver diseases
135. Transection of the esophagus for bleeding esophageal varices
136. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis
137. Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents
138. Depression of the hepatic cytochrome P-450 monooxygenase system by administered tilorone (2,7-bis(2-(diethylamino)ethoxy)fluoren-9-one dihydrochloride)
139. Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents
140. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease
141. Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (Librium)
142. The absorption of intramuscular chlordiazepoxide (Librium) in patients with severe alcoholic liver disease
143. Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure
144. Furosemide disposition in cirrhotic patients
145. Prednisone for chronic active liver disease: Pharmacokinetics, including conversion to prednisolone
146. Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients
147. Chlordiazepoxide and oxazepam disposition in cirrhosis
148. THE EFFECT OF BARBITURATES IN PATIENTS WITH LIVER DISEASE 1
149. Abnormal metabolism of acetaminophen in patients with alcohol liver disease
150. Diphenylhydantoin potency and plasma protein binding
151. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis
152. Effect of alcohol and chronic liver disease on the metabolic disposal of paracetamol in man
153. Interferon-mediated depression of cytochrome P-450-dependent drug biotransformation
154. Homogeneous interferon from E. coli depresses hepatic cytochrome P-450 and drug biotransformation
155. Ranitidine disposition and systemic availability in hepatic cirrhosis
156. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver disease
157. Cimetidine clearance and bioavailability in hepatic cirrhosis
158. Impairment of drug metabolism in polycystic non-parasitic liver disease
159. Measurement of hepatic drug-metabolizing enzyme activity in man
160. Pharmacokinetics and metabolism of theophylline in patients with liver diseases
161. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein
162. Single-dose ceftriaxone kinetics in liver insufficiency
163. Scintillation splenoportography: Hemodynamic and morphological study of the portal circulation
164. Significance of intra- and extrahepatic portasystemic shunting in survival of cirrhotic patients
165. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis
166. The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man
167. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans
168. Systemic availability of lidocaine in patients with liver disease
169. Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease
170. Furosemide disposition in cirrhosis
171. Cimetidine kinetics and dynamics in patients with severe liver disease
172. Triamterene kinetics and dynamics in cirrhosis
173. Furosemide kinetics and dynamics in patients with cirrhosis
174. The influence of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites
175. Pharmacokinetics of atracurium and its metabolites
176. Observations on the metabolic transformation and effects of phenylbutazone in subjects with hepatic disease
177. The effects of liver disease and aging on the disposition of diazepam, chlordiazepoxide, oxazepam and lorazepam in man
178. Influence of viral hepatitis on the disposition of two compounds with high clearance: Lidocaine and indocyanine green
179. Influence of acute viral hepatitis on disposition and pharmacological effect of warfarin
180. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide
181. Naproxen disposition in patients with alcoholic cirrhosis
182. Verapamil disposition in liver disease and intensive care patients: Kinetics, clearance and apparent blood flow relationships
183. Effects of cirrhosis and aging on the elimination and bioavailability of ranitidine
184. Hepatic encephalopathy and altered cimetidine kinetics
185. 3H in patients with acute hepatitis
186. Hexobarbital disposition in compensated and decompensated cirrhosis of the liver